The association between previous statin use and development of atrial fibrillation in patients presenting with acute coronary syndrome

International Journal of Cardiology

Volumn 141, Issue 2, 2010, Pages 147-150

  Ozaydin, Mehmet ^a   Turker, Yasin ^b   Erdogan, Dogan ^a   Karabacak, Mustafa ^a   Dogan, Abdullah ^a   Varol, Ercan ^a   Gonul, Emel ^a   Altinbas, Ahmet ^a  

^a SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b Gulkent Hospital   (Turkey)

Author keywords

Acute coronary syndrome and arrhythmia

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CARDIOVERSION; CONTROLLED STUDY; DRUG USE; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE SIZE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; TREATMENT RESPONSE;

ACUTE CORONARY SYNDROME; AGE FACTORS; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL FIBRILLATION; FEMALE; HEART ATRIA; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED; STROKE VOLUME;

EID: 77952242424     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.11.172     Document Type: Article

References (31)

1. Asanin M., Perunicic J., Mrdovic I., et al. Prognostic significance of new atrial fibrillation and its relation to heart failure following acute myocardial infarction. Eur J Heart Fail 7 (2005) 671-676
2. Goldberg R.J., Yarzebski J., Lessard D., Wu J., and Gore J.M. Recent trends in the incidence rates of and death rates from atrial fibrillation complicating initial acute myocardial infarction: a community-wide perspective. Am Heart J 143 (2002) 519-527
3. Rathore S.S., Berger A.K., Weinfurt K.P., et al. Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes. Circulation 101 (2000) 969-974
4. Crenshaw B.S., Ward S.R., Granger C.B., Stebbins A.L., Topol E.J., and Califf R.M. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience: global utilization of streptokinase and TPA for occluded coronary arteries. J Am Coll Cardiol 30 (1997) 406-413
5. Wong C.K., White H.D., Wilcox R.G., et al. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. Am Heart J 140 (2000) 878-885
6. Eldar M., Canetti M., Rotstein Z., et al. Significance of paroxysmal atrial fibrillation complicating acute myocardial infarction in the thrombolytic era. Circulation 97 (1998) 965-970
7. Pedersen O.D., Bagger H., Kober L., and Torp-Pedersen C. The occurrence and prognostic significance of atrial fibrillation/flutter following acute myocardial infarction. Eur Heart J 20 (1999) 748-754
8. Ozaydin M., Varol E., Aslan S.M., et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 97 (2006) 1490-1493
9. Siu C.W., Lau C.P., and Tse H.F. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 92 (2003) 1343-1345
10. Patti G., Chello M., Candura D., et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 114 (2006) 1455-1461
11. Ozaydin M., Dogan A., Varol E., et al. Statin use before by-pass surgery decreases the incidence and shortens the duration of postoperative atrial fibrillation. Cardiology 107 (2007) 117-121
12. Marin F., Pascual D.A., Roldan V., et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol 97 (2006) 55-60
13. Young-Xu Y., Jabbour S., Goldberg R., et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 92 (2003) 1379-1383
14. Hanna I.R., Heeke B., Bush H., et al. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 3 (2006) 881-886
15. Ramani G., Zahid M., Good C.B., Macioce A., and Sonel A.F. Comparison of frequency of new-onset atrial fibrillation or flutter in patients on statins versus not on statins presenting with suspected acute coronary syndrome. Am J Cardiol 100 3 (Aug 1 2007) 404-405 Electronic publication 2007 Jun 8
16. Mitchell L.B., Powell J.L., Gillis A.M., Kehl V., Hallstrom A.P., and AVID Investigators. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 42 (2003) 81-87
17. Kayikcioglu M., Can L., Evrengul H., Payzin S., and Kultursay H. The effect of statin therapy on ventricular late potentials in a myocardial infarction. Int J Cardiol 90 (2003) 63-72
18. Vyas A.K., Guo H., Moss A.J., et al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 47 4 (Feb 21 2006) 769-773 Electronic publication 2006 Jan 30
19. Dickinson M.G., Ip J.H., Olshansky B., et al. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial SCD-HeFT). Am Heart J 153 4 (Apr 2007) 573-578
20. Ganotakis E.S., Mikhailidis D.P., and Vardas P.E. Atrial fibrillation, inflammation and statins. Hellenic J Cardiol 47 (2006) 51-53
21. Kostapanos M.S., Liberopoulos E.N., Goudevenos J.A., Mikhailidis D.P., and Elisaf M.S. Do statins have an antiarrhythmic activity?. Cardiovas Res 75 (2007) 10-20
22. Dupuis J., Tardif J.C., Cernacek P., and Théroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 99 (1999) 3227-3233
23. Laufs U., La Fata V., Plutzky J., and Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 (1998) 1129-1135
24. Shishehbor M.H., Brennan M.L., Aviles R.J., et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 108 (2003) 426-431
25. Rosenson R.S., and Tangney C.C. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 279 (1998) 1643-1650
26. Tsiara S., Elisaf M., and Mikhailidis D.P. Early vascular benefits of statin therapy. Curr Med Res Opin 19 (2003) 540-556
27. Ridker P.M., Rifai N., Pfeffer M.A., et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with averaged cholesterol levels. Circulation 98 (1998) 839-844
28. Liberopoulos E.N., Daskalopoulou S.S., Mikhailidis D.P., Wierzbicki A.S., and Elisaf M.S. A review of the lipid-related effects of fluvastatin. Curr Med Res Opin 21 (2005) 231-243
29. Lamers J.M., Hartog J.M., Verdouw P.D., and Hülsmann W.C. Dietary fatty acids and myocardial function. Basic Res Cardiol 82 (1987) 209-221
30. Pound E.M., Kang J.X., and Leaf A. Partitioning of polyunsaturated fatty acids, which prevent cardiac arrhythmias, into phospholipid cell membranes. J Lipid Res 42 (2001) 46-51
31. Coats A.J. Ethical authorship and publishing. Int J Cardiol 131 (2009) 149-150